These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. Fu K; Xie F; Wang F; Fu L J Hematol Oncol; 2022 Dec; 15(1):173. PubMed ID: 36482474 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-κB activity via UHRF1/DNMT1 complex. Lin S; Ruan H; Qin L; Zhao C; Gu M; Wang Z; Liu B; Wang H; Wang J Int J Biol Sci; 2023; 19(3):832-851. PubMed ID: 36778111 [TBL] [Abstract][Full Text] [Related]
16. Feiyiliu Mixture sensitizes EGFR Shi J; Hao S; Liu X; Li Y; Zheng X Front Pharmacol; 2023; 14():1093017. PubMed ID: 36744262 [No Abstract] [Full Text] [Related]
17. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports. Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534 [TBL] [Abstract][Full Text] [Related]
18. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668 [TBL] [Abstract][Full Text] [Related]
19. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689 [TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer. Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]